For business leaders, corporate strategists, and growth-focused teams – this report delivers deep market intelligence, forecasts, segmentation, and competitor insights to guide your decisions through 2034.
What are the growth projections for the imfinzi (durvalumab) market from 2024 to 2029?
The imfinzi (durvalumab) market size has grown rapidly in recent years. It will grow from $2,701.22 million in 2024 to $3,013.33 million in 2025 at a compound annual growth rate (CAGR) of 11.6%. The growth in the historic period can be attributed to expanded indications and approvals, demand for targeted therapies, growing patient demand for personalized therapies, improvements in immunotherapy, and rising patient demand for immunotherapies.
The imfinzi (durvalumab) market size is expected to see parid growth in the next few years. It will grow to $4,143.36 million in 2029 at a compound annual growth rate (CAGR) of 11.3%. The growth in the forecast period can be attributed to growing use of combination therapies, increasing pharmaceutical R&D, rising prevalence of cancer, growing acceptance of immunotherapy, increasing regulatory footprint, and growing investment in healthcare facilities. Major trends in the forecast period include adoption of personalized medicine techniques, a focus on personalized medicine, adoption of biosimilars, integration of artificial intelligence and machine learning, and collaborations between pharmaceuticals.
Download Your Free Sample PDF:
https://www.thebusinessresearchcompany.com/sample.aspx?id=19906&type=smp
What strategic initiatives by market players are driving imfinzi (durvalumab) industry growth?
The growing incidence of cancer is expected to drive the growth of the Imfinzi (durvalumab) market going forward. Cancer refers to a group of diseases characterized by the uncontrolled growth and spread of abnormal cells in the body, which can invade and destroy normal tissues. The growing incidence of cancer is largely driven by an aging population, as the risk of cancer increases with age, and by lifestyle factors such as smoking, poor diet, and obesity, which contribute to higher cancer rates. Durvalumab (Imfinzi) is used to treat cancer by inhibiting the PD-L1 protein, which prevents cancer cells from evading detection by the immune system. For instance, in May 2024, according to the National Cancer Institute (NIH), a US-based government agency, in 2022, there were 18.1 million cancer survivors in the U.S., expected to rise to 22.5 million by 2032. Therefore, the growing incidence of cancer is driving the growth of the Imfinzi (durvalumab) market.
The Rise Of Personalized Medicine Fueling Growth In The Imfinzi (durvalumab) Market
Rising personalized medicine is expected to propel the growth of the imfinzi (durvalumab) market going forward. Personalized medicine is a medical approach that tailors treatment and healthcare strategies to the individual characteristics of each patient, such as their genetic makeup, environment, and lifestyle, to achieve the most effective and precise outcomes. The rising personalized medicine is due to advancements in genomic technologies, increased understanding of molecular biology, growing availability of precision diagnostic tools, and the demand for targeted therapies that improve patient outcomes while minimizing side effects. Imfinzi (durvalumab), by targeting and inhibiting the PD-L1 protein, helps personalized medicine by enabling tailored immunotherapy treatments for cancer patients based on the specific tumor biology and immune system characteristics, thereby enhancing treatment efficacy and minimizing unnecessary side effects. For instance, in 2023, according to the Personalized Medicine Coalition, a US-based representative organization, in 2022, the FDA approved personalized medicines for 34% of new drugs, and during the previous eight years, they had been approved for at least 25% of new drugs. Therefore, rising personalized medicine drives the imfinzi (durvalumab) market.
What emerging segments are shaping the future landscape of the imfinzi (durvalumab) industry?
The imfinzi (durvalumab) market covered in this report is segmented –
1) By Type: 2.4mL Injection; 10mL Injection
2) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
3) By Application: Locally Advanced Urothelial Carcinoma; Metastatic Urothelial Carcinoma; Other Applications
View The Full Market Report:
https://www.thebusinessresearchcompany.com/report/imfinzi-durvalumab-global-market-report
Which sustainability trends are emerging in the imfinzi (durvalumab) market?
The key trend in the imfinzi (durvalumab) market is focusing on getting regulatory approvals to expand its use for additional cancer types, enhance its clinical indications, and increase market reach. Regulatory approvals refer to the formal authorization granted by government health authorities, such as the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA), for a drug, medical device, or treatment to be marketed and used in specific regions. For instance, in September 2022, AstraZeneca, a UK-based pharmaceutical company, received FDA approval for durvalumab (Imfinzi) for the treatment of locally advanced or metastatic biliary tract cancer (BTC) in adults, based on the results of the TOPAZ-1 trial. This pivotal study demonstrated that durvalumab, when combined with gemcitabine and cisplatin, significantly improved overall survival (12.8 months vs. 11.5 months for placebo) and progression-free survival (7.2 months vs. 5.7 months). The trial involved 685 patients with various forms of BTC, and common side effects included fatigue, nausea, and abdominal pain. The recommended dosage is 1,500 mg every three weeks during combination therapy, followed by monotherapy every four weeks.
How are key players in the imfinzi (durvalumab) market strengthening their market position?
Major companies operating in the imfinzi (durvalumab) market include AstraZeneca PLC.
Which geographic areas are contributing significantly to the growth of the imfinzi (durvalumab) sector?
North America was the largest region in the imfinzi (durvalumab) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the imfinzi (durvalumab) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
How Can Companies Use The Imfinzi (durvalumab) Market Report to Drive Business Results?
This report provides actionable insights tailored for business use—not academic analysis. Companies can leverage the data to:
• Time market entry or expansion using growth forecasts and CAGR trends.
• Develop competitive products by tracking key technology shifts and user preferences.
• Tailor regional strategies with in-depth geographic data and local market dynamics.
• Benchmark and plan partnerships using competitive landscape insights.
Purchase The Report And Get A Swift Delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=19906
Need Customized Data On Imfinzi (durvalumab) Market?
For companies needing more tailored intelligence, The Business Research Company offers customized consulting and data services. Whether you’re entering new regions, launching innovative products, or assessing M&A opportunities, our experts can develop actionable insights specific to your business objectives.
Request Customized Data:
https://www.thebusinessresearchcompany.com/customise?id=19906&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
